In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), and reduced the price …
In a research report released Friday, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR) and raised the …
Chardan analyst Gbola Amusa came out today with some commentary on Esperion Therapeutics Inc (NASDAQ:ESPR)’s top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety …
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on Axovant Sciences Ltd. (NYSE:AXON) with a $9.
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), while reducing the price target from …
In a research report published Monday, Chardan analyst Gbola Amusa reiterated a Neutral rating on shares of Avalanche Biotechnologies Inc (NASDAQ:AAVL), while reducing the price …
In a research report published Tuesday, Chardan analyst Gbola Amusa upgraded shares of Avalanche Biotechnologies Inc (NASDAQ:AAVL) from Sell to Neutral rating, as his price …
Chardan analyst Gbola Amusa weighed in today with a negative report on Esperion Therapeutics Inc (NASDAQ:ESPR), reducing the price target to $55 (from $50), while reiterating …
In a research report released Friday, Chardan analyst Gbola Amusa initiated coverage on shares of Uniqure NV (NASDAQ:QURE) with a Buy rating and a $40 …
